Aubrey Dan explains how EmpowerPharm developed its synthetic CBD tablet and why a novel formulation could help combat a range of indications.
With the continued interest in the opportunities that cannabinoids offer, it makes sense that all avenues are being pursued. EmpowerPharm Inc has chosen the route of developing a new synthetic cannabidiol (CBD) tablet that could help combat mental health issues – specifically anxiety during the COVID-19 pandemic.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
European Pharmaceutical Review’s Victoria Rees spoke with Aubrey Dan, Co-founder and Executive Chairman of EmpowerPharm to find out how the new synthetic CBD tablet was developed and what went into establishing their good manufacturing practice (GMP)-compliant facility.
Why develop synthetic CBD?
Dan said that the synthetic form of CBD has a broad range of therapeutic potential, with previous research showing anecdotal evidence on symptoms of anxiety, stress, pain and insomnia. Mostly it has been formulated so that it can be administered with smoking, vaping or in oil drops.
Instead, he wanted to transform CBD into a pharmaceutical and standardised product that could be prepared into a tablet with an active pharmaceutical ingredient (API) that is synthetically derived that is 99.9 percent pure and has no tetrahydrocannabinol (THC). One benefit of this, he explained, is that other pharmaceuticals used for anxiety such as benzodiazepines, can be highly addictive and cause problems for patients. Therefore, a non-addictive CBD is a solution and alternative to this issue.
Similarly, some research has shown CBD can help with the reduction of opioid use. “If I am able to help contribute towards the reduction of [opioid use] and improve society by managing the situation then that is the biggest way to give back to society that pharmaceuticals can offer right now – especially in light of what is happening with COVID-19.”
Why not use CBD oil extract?
Products that contain CBD oil extract have potency in the range of 65 to 80 percent instead of 99.9 percent, Dan explained, while the remaining amount are various naturally occurring cannabinoids including traces of THC as well as other substances of varying qualitative and quantitative composition due to batch and season variability. Cannabis CBD extracts therefore lack the rigorous standardisation required and strict pharmaceutical specifications so would not meet current quality guidelines and regulatory requirements to be approved as a drug.
The first steps
Dan explained that when EmpowerPharm began their development process, the research team were looking to find a derivative from hemp that could be crystallised. They identified a potential source for this derivative in Europe; however, they soon realised that the scale this could be produced was not sufficient for their needs.
“The biggest challenge was sourcing the API CBD from a GMP source,” Dan said, adding that there are only a few manufacturers that make the products they required in a GMP manner. “Finding the right one was not a simple task.” He emphasised that many API suppliers claim their products are GMP-certified despite being outsourced to third-party companies who do not have GMP certification by a federally regulated body. While there were some options for suppliers in Europe, they were lucky to find one locally in Canada.
This supplier had already synthesised a CBD API that was GMP-approved by Health Canada, the US Food and Drug Administration (FDA) and in Japan and the company had already developed it from a pilot batch to a large scale batch.
One year later, this partnership enabled EmpowerPharm to develop a novel tablet formulation, which Dan summarised as their path “from API to a finished tablet form.” He said that now, their next step is to enter a Phase I clinical trial.
Establishing a GMP facility
The company has developed a new GMP pharmaceutical manufacturing facility in Burlington, Canada. According to Dan, with their facility the company will soon be ready to conduct clinical batch manufacturing, testing and release for their Phase I clinical trial.
“Within a few months we anticipate that Health Canada will perform a full inspection for our Drug Establishment Licence (DEL) – depending upon how things are with COVID-19,” Dan said. “We have gone through the entire process of our standard operating procedures and quality systems, ensuring that our quality controls and management systems are all up to speed.”
Developments in the cannabinoid market
Looking forward, Dan is excited to see further developments in the cannabinoid market. The company has been approached by leading academic institutions looking to work together on clinical research to further understand the benefits of CBD on other indications.
“I think there will be more and more sophistication and broad applications for CBD,” said Dan. As a potential first-line therapy, specifically with pain, anxiety, stress and insomnia, he predicts that Empower CBDTM has the potential to be highly useful in the physician’s toolkit.
Read our previous instalment in the Cannabinoid series by clicking here.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.